Back to discover
Drug

Edetic Acid

In clinical development
Emerging researchLate-stage development
Also known as (ethylenedinitrilo)tetraacetic acid, ion(4-), Acide edetique, Acide ethylenediaminetetracetique, Acido edetico+10 more

(ethylenedinitrilo)tetraacetic acid, ion(4-), Acide edetique, Acide ethylenediaminetetracetique, Acido edetico, Acidum edeticum, Disotate, EDTA, EDTA, ion(4-), Endrate, Ethylene diamine tetra acetic acid, Ethylenediaminetetraacetic Acid, Meritate, Edetate Disodium, N,N'-1,2-Ethane diylbis-(N-(carboxymethyl)glycine).

2
Research papers
1
Active clinical trials
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this drug.

Trial to Assess Chelation Therapy in Critical Limb Ischemia

Clinical trial2026-07-01Results expected Q4 2026 · ClinicalTrials.gov

PSMA PET/CT: joint EANM procedure guideline/SNMMI procedure standard for prostate cancer imaging 2.0.

Research2023-01-05European journal of nuclear medicine and molecular imaging

Ethanolic Extract of Sapindus Mukorossi as the Final Endodontic Irrigant.

Clinical trial2021-09-01Completed · ClinicalTrials.gov

Trial to Assess Chelation Therapy (TACT)

Clinical trial2013-11-05Results posted · ClinicalTrials.gov

Profile

Identifiers & mechanism

Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.

Canonical name
Edetic Acid
Aliases & brands
(ethylenedinitrilo)tetraacetic acid, ion(4-)Acide edetiqueAcide ethylenediaminetetracetiqueAcido edeticoAcidum edeticumDisotateEDTAEDTA, ion(4-)EndrateEthylene diamine tetra acetic acidEthylenediaminetetraacetic AcidMeritateEdetate DisodiumN,N'-1,2-Ethane diylbis-(N-(carboxymethyl)glycine)
RxNorm CUI
3755
ChEMBL ID
CHEMBL858
UNII
9G34HU7RV0

Clinical trials

7 trials

The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.

Development programme
CLINICALTRIALS.GOV · LIVE REGISTRY
7
registered trials across all phases
LATEST COMPLETION 2025
1
Active studies
6
Late-stage (III+)
6
Completed
PHASE DISTRIBUTIONn = 7
Phase 21Phase 2 / 31Phase 32Phase 41Phase N / A2

Late-stage studies

Phase III+ trials still open or recently active — where late-stage evidence is being generated.

Recent completions

Trials that read out recently, adding to the completed evidence base.

Research activity

2 papers

Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.

Publications over time
20232024
Major research themes8
Positron Emission Tomography Computed Tomography2Dipeptides1Gallium Isotopes1Gallium Radioisotopes1Heterocyclic Compounds, 1-Ring1Lutetium1Prostatic Neoplasms1Prostatic Neoplasms, Castration-Resistant1
Journals, researchers & institutions
Top journals
  • European journal of nuclear medicine and molecular imaging1
  • Radiology1
Leading researchers
  • Herrmann K2
  • Adra N1
  • Armstrong AJ1
  • Beheshti M1
  • Benson T1
  • Bomanji J1
  • Brackman M1
  • Calais J1
Leading institutions
free-text, unnormalised
  • Amsterdam University Medical Centers1
  • Banner MD Anderson Cancer Center1
  • Center for Cancer Research1
  • Dana-Farber Cancer Institute/Brigham and Women's Hospital1
  • Emory University School of Medicine1
  • From the University of Arizona1

Related drugs

2 matches

Drugs sharing diseases, protein targets and literature with this one. Ranked by graph evidence (shared targets + diseases weighted above co-mentions).

Studied across the same disease area as Edetic Acid in the shared literature.

1 shared disease1 shared paper

Studied across the same disease area as Edetic Acid in the shared literature.

1 shared disease1 shared paper
References & data sources
  • RxNorm (U.S. National Library of Medicine) — drug identity
  • ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
  • Europe PMC — research literature
  • ClinicalTrials.gov — clinical trials